Boehringer Ingelheim launches vaccine for three poultry diseases
Boehringer Ingelheim Animal Health announced the U.S. launch of its Vaxxitek HVT+IBD+ILT vaccine, which targets three poultry diseases.
According to the company, this is the first vaccine to offer protection in one shot from infectious laryngotracheitis, Marek’s disease and infectious bursal disease (classic and variant types). It uses the same bioengineering platform as Vaxxitek HVT+IBD, which Boehringer Ingelheim said has protected more than 100 billion birds from Marek’s disease and infectious bursal disease in more than 75 countries since its introduction in 2006.
Infectious laryngotracheitis is a highly contagious respiratory disease in poultry caused by Gallid alpha herpesvirus type 1, also known as infectious laryngotracheitis virus. The virus persists in affected birds for life. After recovery, they can still infect other birds. The disease can cause major economic losses, according to Boehringer Ingelheim’s announcement.
“This new trivalent vaccine provides a strong immune foundation, optimizes protection for flocks and offers reliable protection,” said Matt Nelson, head of Boehringer Ingelheim Animal Health’s U.S. poultry business.
The company will manufacture the vaccine in Gainesville, Georgia. After the U.S. launch, the company plans to seek regulatory approval in other countries.